Publication:
Cost-effectiveness of exercise training to improve claudication symptoms in patients with peripheral arterial disease

dc.contributor.authorTreesak C.
dc.contributor.authorKasemsup V.
dc.contributor.authorTreat-Jacobson D.
dc.contributor.authorNyman J.A.
dc.contributor.authorHirsch A.T.
dc.date.accessioned2021-04-05T04:32:44Z
dc.date.available2021-04-05T04:32:44Z
dc.date.issued2004
dc.date.issuedBE2547
dc.description.abstractExercise rehabilitation is a proven, yet poorly available, treatment for intermittent claudication, the primary symptom of peripheral arterial disease (PAD). Exercise rehabilitation is effective, non-invasive, and associated with minimal cardiovascular risk in appropriate patients. Percutaneous transluminal angioplasty (PTA), especially of the iliac segment, is an alternative effective treatment for claudication. There are, however, minimal data currently available to compare the cost-effectiveness of these two interventions. We compared the cost-effectiveness of 3- and 6-month exercise programs with that of iliac PTA without stenting, using the incremental cost-effectiveness ratio [ICER = (Cost2 - Cost1)/(Effectiveness2 - Effectiveness1)]. The ICER represented the price of an additional meter walked derived from each treatment based on conservative models of success of each procedure and specific care assumptions. PTA and exercise efficacy data were derived from a literature review and exercise costs were modeled per the current CPT code 93668. Effectiveness was defined as absolute claudication distance (ACD) at 3 and 6 months. Three treatment alternatives were assessed: (1) no treatment, (2) PTA, and (3) exercise rehabilitation. At 3 months, PTA was more effective than exercise therapy and resulted in an additional 38 meters at an additional cost of $ 6719, for an ICER of $177/meter. At 6 months, however, exercise was more effective than PTA, resulting in an additional 137 meters walked, and costs less ($61 less per meter gained). In conclusion, exercise rehabilitation at 6 months is more effective and costs less than PTA, and is therefore cost-saving. The cost-effectiveness and availability of claudication treatments has national implications for future PAD care; however, data to inform these care choices can best be obtained in prospective clinical trials. © Arnold 2004.
dc.format.mimetypeapplication/pdf
dc.identifier.citationVascular Medicine. Vol 9, No.4 (2004), p.279-285
dc.identifier.doi10.1191/1358863x04vm570oa
dc.identifier.issn1358863X
dc.identifier.other2-s2.0-13444267774
dc.identifier.urihttps://hdl.handle.net/20.500.14740/6384
dc.rights.holderScopus
dc.subject.otherArticle
dc.subject.otherClaudication
dc.subject.otherControlled study
dc.subject.otherCost effectiveness analysis
dc.subject.otherData analysis
dc.subject.otherHuman
dc.subject.otherIntermethod comparison
dc.subject.otherKinesiotherapy
dc.subject.otherMedical literature
dc.subject.otherNonbiological model
dc.subject.otherPercutaneous transluminal angioplasty
dc.subject.otherPeripheral occlusive artery disease
dc.subject.otherPriority journal
dc.subject.otherSymptomatology
dc.subject.otherWalking
dc.subject.otherAngioplasty, Balloon
dc.subject.otherCost-Benefit Analysis
dc.subject.otherExercise Therapy
dc.subject.otherFemale
dc.subject.otherFollow-Up Studies
dc.subject.otherHumans
dc.subject.otherIntermittent Claudication
dc.subject.otherLower Extremity
dc.subject.otherMale
dc.subject.otherPatient Compliance
dc.subject.otherPeripheral Vascular Diseases
dc.subject.otherProgram Evaluation
dc.subject.otherTreatment Outcome
dc.subject.otherUnited States
dc.titleCost-effectiveness of exercise training to improve claudication symptoms in patients with peripheral arterial disease
dc.typeArticle
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-13444267774&doi=10.1191%2f1358863x04vm570oa&partnerID=40&md5=9faf599c653e2114e27ef5f44623a63f

Files